Close

Amgen (AMGN) Announces Erenumab Phase 3 Met Primary Endpoint in Migraine Prevention

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/16/2024

1. SPY
2. AMD
3. GS
4. JNJ
5. BAC
6. UNH
7. TSLA
8. BK
9. MS
10. SCHW


Go back to Amgen (AMGN) Announces Erenumab Phase 3 Met Primary Endpoint in Migraine Prevention
Amgen Inc (NASDAQ: AMGN) Delayed: 264.87 -0.64 (0.24%)
Previous Close $265.51    52 Week High $176.85 
Open $266.83    52 Week Low $133.64 
Day High $267.51    P/E 39.89 
Day Low $263.81    EPS $6.64 
Volume 500,345